SinoMab BioScience Buchwert je Aktie
Was ist das Buchwert je Aktie von SinoMab BioScience?
Buchwert je Aktie von SinoMab BioScience Limited ist 0.23
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf HKSE im Vergleich zu SinoMab BioScience
Was macht SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Unternehmen mit buchwert je aktie ähnlich SinoMab BioScience
- Onxeo SA hat Buchwert je Aktie von 0.23
- Stereotaxis hat Buchwert je Aktie von 0.23
- Solomon Systech (International) hat Buchwert je Aktie von 0.23
- Summa Silver hat Buchwert je Aktie von 0.23
- Standard Mercantile Acquisition hat Buchwert je Aktie von 0.23
- Eagle Health hat Buchwert je Aktie von 0.23
- SinoMab BioScience hat Buchwert je Aktie von 0.23
- Qurate Retail Inc hat Buchwert je Aktie von 0.23
- NorthIsle Copper and Gold hat Buchwert je Aktie von 0.23
- Zhongguancun Science-Tech hat Buchwert je Aktie von 0.23
- Klondike Gold hat Buchwert je Aktie von 0.23
- Applied Development hat Buchwert je Aktie von 0.23
- SH () hat Buchwert je Aktie von 0.23